Related Experiment Video
Updated: Aug 24, 2025
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
Published on: January 2, 2017
Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development
Tanapati Phakham1,2, Chatikorn Boonkrai1,2, Tossapon Wongtangprasert2,3
1Interdisciplinary Program of Biomedical Sciences, Graduate School, Chulalongkorn University, Bangkok, Thailand.
Abstract:
Programmed cell death protein 1 (PD-1) plays a significant role in suppressing antitumor immune responses. Cancer treatment with immune checkpoint inhibitors (ICIs) targeting PD-1 has been approved to treat numerous cancers and is the backbone of cancer immunotherapy. Anti-PD-1 molecule is necessary for next-generation cancer immunotherapy to further improve clinical efficacy and safety as well as integrate into novel treatment combinations or platforms. We developed a highly efficient hybridoma generation and screening strategy to generate high-potency chimeric anti-PD-1 molecules. Using this strategy, we successfully generated several mouse hybridoma and mouse/human chimeric clones that produced high-affinity antibodies against human PD-1 with high-quality in vitro PD-1/PD-L1 binding blockade and T cell activation activities. The lead chimeric prototypes exhibited overall in vitro performance comparable to commercially available anti-PD-1 antibodies and could be qualified as promising therapeutic candidates for further development toward immuno-oncology applications.
Insights
Researchers developed a new strategy to create potent anti-PD-1 antibodies for cancer immunotherapy. These novel immune checkpoint inhibitors show promise for improving cancer treatment efficacy and safety.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Programmed cell death protein 1 (PD-1) is a key regulator of immune responses, often exploited by tumors to evade immune surveillance.
- Immune checkpoint inhibitors (ICIs) targeting PD-1 are a cornerstone of modern cancer immunotherapy, demonstrating efficacy across various malignancies.
- There is a continuous need for next-generation anti-PD-1 therapies with enhanced potency, safety, and compatibility with combination strategies.
Purpose of the Study:
- To develop an efficient hybridoma generation and screening strategy for producing high-potency chimeric anti-PD-1 antibodies.
- To identify and characterize novel anti-PD-1 antibody candidates for immuno-oncology applications.
Main Methods:
- Implementation of a novel hybridoma generation and screening platform.
- Development of mouse hybridoma and mouse/human chimeric antibody clones targeting human PD-1.
- In vitro assessment of antibody-derived clones for PD-1/PD-L1 binding blockade and T cell activation.
Main Results:
- Successful generation of multiple high-affinity chimeric anti-PD-1 antibody clones.
- Demonstrated high-quality in vitro blockade of PD-1/PD-L1 interactions.
- Exhibited potent T cell activation capabilities.
- Lead chimeric prototypes showed in vitro performance comparable to existing commercial anti-PD-1 antibodies.
Conclusions:
- The developed hybridoma strategy is effective for generating high-potency anti-PD-1 antibodies.
- The identified chimeric anti-PD-1 antibodies are promising therapeutic candidates for immuno-oncology.
- These novel antibodies could advance next-generation cancer immunotherapy development.
